Loading…
← CockpitCompetitor Analysis › ADUS Addus HomeCare CorporationOpen in the cockpit ↗

Addus HomeCare CorporationADUSCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services

Provider of home care services including personal care, hospice and home health, mainly for Medicaid-eligible seniors.

Momentum strong 78
Mkt cap
$2.25B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$32.3M
20-day average traded
Fwd P/E
16.2×
forward earnings
ROIC−WACC
+2.8 pp
WACC 8.7%
Hurdle
-9 pp
Req g minus delivered
Next earnings
103 days
1 Mar 2027
Close · USD$120.85
1D-0.6%
1W-3.7%
1M+2.4%
3M+0.2%
6M+28.9%
YTD+12.5%
1Y+12.1%
ATR %3.0%
Beta-0.02
52w lowhigh8.2% off high

What Addus HomeCare does

Provider of home care services including personal care, hospice and home health, mainly for Medicaid-eligible seniors.

Paid mostly by state programs such as Illinois's, which set an hourly rate for personal care, so state budgets and wage rules matter more than competition. Personal care is the base, while hospice and home health, paid by Medicare, are faster-growing parts. It has grown by buying smaller agencies.

Products and services

  • Personal care services
  • Hospice care
  • Home health services

Customers

  • Medicaid-eligible seniors/disabled individuals
  • State Medicaid programs

Where it sits in the supply chain

  • Health care services
  • Home care services
  • Personal care, hospice & home health…

What could go right

  • Aging-in-place demand growth
  • State Medicaid home-care reimbursement increases

What could go wrong

  • Caregiver labor shortage/wage inflation
  • Medicaid reimbursement rate risk

Moat: narrow (scale, regulatory licence). State Medicaid contracts and multi-state licensure create barriers for smaller regional home-care providers.

Headquarters: Frisco, Texas · Founded: 1979 · Employees: 50,659

Named competitors

Addus HomeCare at a glance

Size Addus HomeCare (ADUS) is a United States Health Care company (Medical/Nursing Services) with a market value of $2.25B, the 1702nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $120.85 on 18 Nov 2026.

Performance Over six months the shares gained 28.9%, against +19.1% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 11.5% over the last twelve months (peer median +4.6%); the operating margin is 11.1% (peer median 7.5%).

Valuation It trades at 16.2× forward earnings against a peer median of 39.5× (4th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -9 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.8 points above its cost of capital (8.7% WACC).

Short interest Short interest is 5.3% of the free float (30 Oct 2026).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026ADUS 130Peer median 120
Six months, rebased to 100: Addus HomeCare against the median of its 20 peers (local-currency closes).

Addus HomeCare financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.50B$1.42B$1.15B$1.06B$951M
Revenue growth—+23%+9%+11%—
Gross profit$469M$445M$361M$329M$290M
EBITDA$184M$165M$129M$111M$93.5M
Net income$111M$95.9M$73.6M$62.5M$46.0M
Free cash flow$144M$104M$110M$103M$96.8M
Capital expenditure$7.82M$7.72M$6.05M$9.45M$8.30M
Total debt$67.3M$171M$273M$175M$178M

Quarterly statements and history in the cockpit →

Addus HomeCare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%AVAHALIF-BMDAZTANEO002044AGARWALEYE603882EMEIS300244VIJAYAPSNLSNDAAMBEAWGSAGLTDOCACHC4544LALPATHLABADUS6-month return →1-month return →
Up and to the right = strong over both horizons. Addus HomeCare is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%25×50×75×AVAHALIF-BMDAZTANEO002044AGARWALEYE603882300244VIJAYAAMBEAWGSAGLACHCLALPATHLABADUSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Addus HomeCare is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%AVAHALIF-BMDAZTA002044AGARWALEYE603882EMEIS300244VIJAYAAMBEATDOC4544LALPATHLABADUSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Addus HomeCare is the large dot.

Addus HomeCare competitors and peer comparison

Head to head with its named competitors (ADUS vs AVAH vs BTSG vs PNTG)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Addus HomeCare ADUS$2.25B+29%+12%11%16.2×4.0%
Aveanna Healthcare AVAH$2.37B+41%+17%12%12.2×7.7%
BrightSpring Health Services BTSG$13.6B+17%+23%4%28.8×24.9%
Pennant PNTG$1.26B+1%+39%6%23.7×20.7%
Chemed CHE$7.12B+24%+5%14%20.2×3.3%

How Addus HomeCare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Addus HomeCare against its 20 peers (data as of 18 Nov 2026)
MeasureADUSPeer medianRank in peer set
1-month return+2.4%-0.3%10th highest of 21
6-month return+28.9%+19.1%7th highest of 21
Distance from 52-week high-8.2%-19.6%9th highest of 21
Revenue growth (TTM)+11.5%+4.6%8th highest of 21
Operating margin11.1%7.5%6th highest of 21
Forward P/E16.2×39.5×4th cheapest of 17
Growth the price implies (Req g, 7 yrs)4.0%8.7%5th least demanding of 15
Growth delivered (Del g)+13.2%+8.1%5th highest of 15
Hurdle (Req g minus delivered)-9.2 pp+7.0 pp2nd least demanding of 15
ROIC minus cost of capital+2.8 pp-1.7 pp6th highest of 20
EV / EBITDA12.1×11.7×7th most expensive of 14
Net debt / EBITDA-0.2×2.2×3rd least indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Addus HomeCare ADUSUnited States$2.25B+29%+12%11%16.2×4.0%+13.2%
Aveanna Healthcare AVAHUnited States$2.37B+41%+17%12%12.2×7.7%+10.2%
AddLife ALIF-B.STSweden$2.13B+15%+2%8%39.0×21.1%+14.6%
Pediatrix Medical MDUnited States$2.41B+37%+2%12%12.4×-4.4%+2.0%
Azenta AZTAUnited States$2.03B+162%+5%-2%83.2×38.0%+3.9%
NeoGenomics NEOUnited States$1.98B+72%+11%-6%53.5×n/an/a
Meinian Onehealth Healthcare 002044.SZChina$2.60B-27%-4%9%49.6×4.2%+5.7%
Dr. Agarwal's Health Care AGARWALEYE.NSIndia$1.86B+20%+26%15%77.1×43.0%+26.9%
Guangzhou Kingmed Diagnostics 603882.SSChina$1.86B+5%-3%7%29.9×5.4%-6.1%
Emeis EMEIS.PAFrance$1.78B-33%+4%3%n/a21.2%+8.5%
Dian Diagnostics 300244.SZChina$1.70B+1%-5%9%21.8×0.3%-1.1%
Vijaya Diagnostic Centre VIJAYA.NSIndia$1.69B+18%+24%32%63.0×40.4%+16.7%
Personalis PSNLUnited States$1.62B+88%+17%-157%n/an/an/a
Sonida Senior Living SNDAUnited States$1.59B-11%+70%-8%n/an/an/a
Ambea AMBEA.STSweden$1.59B+28%+11%9%15.2×1.1%+7.7%
GeneDx WGSUnited States$1.56B+16%+15%-14%54.2×n/an/a
agilon health AGLUnited States$1.52B+12%+2%-2%34.1×n/an/a
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%n/a-6.4%+18.3%
Acadia Healthcare ACHCUnited States$3.49B+56%+4%10%18.6×n/an/a
H.U.Group 4544.TJapan$1.44B+24%+1%3%39.9×9.7%+2.1%
Dr. Lal PathLabs LALPATHLAB.NSIndia$3.53B+15%+17%24%50.5×32.3%+11.8%

Questions

Who are Addus HomeCare's main competitors?
Named competitors: Amedisys (private or unlisted), Aveanna Healthcare (AVAH), BrightSpring Health Services (BTSG), Pennant Group (PNTG), Enhabit (private or unlisted), Chemed (CHE). The cockpit's measured peer set (industry) also includes Aveanna Healthcare (AVAH), AddLife (ALIF-B.ST), Pediatrix Medical (MD), Azenta (AZTA), NeoGenomics (NEO), Meinian Onehealth Healthcare (002044.SZ).
Is Addus HomeCare expensive compared with its peers?
On forward p/e it trades at 16.2× against a peer median of 39.5×, 4th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -9 pp: the price already allows for a slowdown.
How has Addus HomeCare stock performed?
Over six months to 18 Nov 2026 the shares returned +28.9% against +19.1% for the median peer; over one year +12.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.